PCL, Inc. (KOSDAQ:241820)

Market Cap	22.60B
Revenue (ttm)	8.49B
Net Income (ttm)	-13.28B
Shares Out	59.17M
EPS (ttm)	-186.73
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	386,285
Average Volume	533,916
Open	382.00
Previous Close	382.00
Day's Range	372.00 - 385.00
52-Week Range	372.00 - 2,190.00
Beta	0.19
RSI	24.58
Earnings Date	Mar 21, 2025

About PCL, Inc.

PCL, Inc. provides multiplex in vitro diagnostic (IVD) products and platform services. The company offers HiSU solution, an automated multi-immune diagnostic system that performs various diagnostics, high-speed tests including blood screening, multiple cancer screening, autoimmune testing, etc. It also provides antigen and antibody diagnostic kits, including PCLOK II anti-HIV/HCV/syphilis, and PCLOK II HBsAg/HIV p24. In addition, the company offers platform services, such as SG ID for identifying novel target substances. Further, it offers covi...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2008
• Employees: 31
• Stock Exchange: KOSDAQ
• Ticker Symbol: 241820

Financial Performance

In 2023, PCL, Inc.'s revenue was 8.43 billion, a decrease of -77.35% compared to the previous year's 37.22 billion. Losses were -20.32 billion, 405.7% more than in 2022.